WithdrawnEarly Phase 1

Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation

Stopped: Study was never started

United States0Started 2020-12

Plain-language summary

We will study 40 matched patients. 20 patients will receive leukoreduced whole blood from the solid organ donor. These 20 patients will be compared to 20 historical matched controls with regards to allogenic blood product usage and other physiologic markers

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \- Recipients 18 years or older. * Deceased donor whole graft liver transplant recipients undergoing liver transplant starting 07/01/2020 and onwards at VUMC. * ABO-matched recipient and donor. * Donor Hb level \>/= 8 g/dL * Recipients with negative ABO antibody screen Exclusion Criteria: * \- Pediatric recipient. * HBS Antigen+ donors * HCV NAT+ donors * Donors of A2 blood type * Donors on oral anticoagulants (except for aspirin) over the past 3 days before organ procurement

What they're measuring

Use of allogenic banked blood products

Timeframe: perioperative up to 72 hours post operative

Economic cost

Timeframe: perioperative up to 72 hours post operative

Trial details

NCT IDNCT04383756

SponsorVanderbilt University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-07

View on ClinicalTrials.gov More Transfusion Related Complication trials